Eli Lilly and Company has announced promising findings from a recent trial evaluating its new daily oral GLP-1 medication, orforglipron, for obesity management. Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, said: “We are thrilled about the potential of this oral therapy. He thinks it’s an enormous leap forward for obesity care.
During the trial, nearly all of the eligible participants engaged. Approximately 10% chose to discontinue use of the pill. This information is essential, as it helps paint a picture of the medication’s tolerability and adherence for end users. Eli Lilly, Lilly Corporate Center, Indianapolis, Indiana, Eli Lilly passionately pursues Cardiometabolic Health. They recognize the need to address the quickly escalating challenges of obesity and other adverse conditions.
Custer commented on the motivation behind developing orforglipron, stating, “With orforglipron, we’re working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments.”
The trial’s results indicate the treatable oral alternative could be a more accessible option. This is a hopeful new development for people living with obesity who want safe, effective treatment. Injectable therapies bring their own set of challenges. The launch of an easy-to-use daily pill would have a seismic impact on how health care providers treat and the populations they serve manage obesity.
The Eli Lilly logo lights up the roof of the company’s headquarters in Indianapolis. It represents their deep commitment to advancing innovation in the healthcare sector. Photo by Scott Olson/Getty Images, photo of Chicago’s welcoming sign on St. Patrick’s Day 2024. More importantly, it reflects everything that’s still developing and changing inside the organization.
Eli Lilly and Company remains committed to changing the treatment landscape for obesity by significantly investing in innovative research and development. The company has a robust pipeline of ongoing trials and real-world evidence evaluations of orforglipron. They are passionate about making a difference in patient outcomes in Cardiometabolic Health.
